{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"94"}],"units":"Participants"}],"title":"FRE Neg Participants"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"}],"units":"Participants"}],"title":"FRE Positive Participants"}],"denoms":[{"counts":[{"groupId":"OG000","value":"117"}],"units":"Participants"}],"description":"Occurrence of neutropenic fever during the first 28 days (4 weeks) after autologous PBSC transplantation in the treatment of multiple myeloma.","groups":[{"description":"Subjects eligible for this study will meet the defined eligibility criteria to undergo autologous transplantation established at the transplant centers as per standard of care (SOC). All adult patients with a diagnosis of multiple myeloma undergoing autologous transplantation after dose-intense melphalan conditioning are candidates for enrollment into this study. These subjects will be approached for enrollment into this study by the transplant attending physician caring for the patient","id":"OG000","title":"Enrolled Participants"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Analysis separated by FRE Positive and Negative Participants","reportingStatus":"POSTED","timeFrame":"Within 28 days of the transplantation","title":"Occurrence/Risk of Febrile Neutropenia (FN)","type":"SECONDARY","unitOfMeasure":"Participants"}